{"id":"https://openalex.org/W2004302235","doi":"https://doi.org/10.1517/14656566.2015.1016912","title":"Nanoparticle albumin-bound-paclitaxel: a limited improvement under the current therapeutic paradigm of pancreatic cancer","display_name":"Nanoparticle albumin-bound-paclitaxel: a limited improvement under the current therapeutic paradigm of pancreatic cancer","publication_year":2015,"publication_date":"2015-04-17","ids":{"openalex":"https://openalex.org/W2004302235","doi":"https://doi.org/10.1517/14656566.2015.1016912","mag":"2004302235","pmid":"https://pubmed.ncbi.nlm.nih.gov/25887245","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/5559227"},"language":"en","primary_location":{"id":"doi:10.1517/14656566.2015.1016912","doi":"https://doi.org/10.1517/14656566.2015.1016912","is_oa":true,"landing_page_url":"https://doi.org/10.1517/14656566.2015.1016912","pdf_url":"https://www.tandfonline.com/doi/pdf/10.1517/14656566.2015.1016912?needAccess=true&role=button","source":{"id":"https://openalex.org/S52020611","display_name":"Expert Opinion on Pharmacotherapy","issn_l":"1465-6566","issn":["1465-6566","1744-7666"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Pharmacotherapy","raw_type":"journal-article"},"volume":null,"type":"editorial","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://www.tandfonline.com/doi/pdf/10.1517/14656566.2015.1016912?needAccess=true&role=button","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5040819666","display_name":"Robert M. Hoffman","orcid":"https://orcid.org/0000-0002-0049-0041","observed_orcids":["https://orcid.org/0000-0002-0049-0041"]},"institutions":[{"id":"https://openalex.org/I36258959","display_name":"University of California San Diego","ror":"https://ror.org/0168r3w48","country_code":"US","type":"education","lineage":["https://openalex.org/I36258959"]},{"id":"https://openalex.org/I4210121314","display_name":"AntiCancer (United States)","ror":"https://ror.org/02pp1v282","country_code":"US","type":"company","lineage":["https://openalex.org/I4210121314"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert M Hoffman","raw_affiliation_strings":["AntiCancer, Inc. , 7917 Ostrow Street, San Diego, 92111 CA , USA +1 858 654 2555 ; +1 858 268 4175 ; all@anticancer.com","+1 858 268 4175","AntiCancer, Inc., 7917 Ostrow Street, San Diego, 92111 CA, USA +1 858 654 2555","University of California San Diego, Department of Surgery, San Diego, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AntiCancer, Inc. , 7917 Ostrow Street, San Diego, 92111 CA , USA +1 858 654 2555 ; +1 858 268 4175 ; all@anticancer.com","institution_ids":["https://openalex.org/I4210121314"]},{"raw_affiliation_string":"+1 858 268 4175","institution_ids":[]},{"raw_affiliation_string":"AntiCancer, Inc., 7917 Ostrow Street, San Diego, 92111 CA, USA +1 858 654 2555","institution_ids":["https://openalex.org/I4210121314"]},{"raw_affiliation_string":"University of California San Diego, Department of Surgery, San Diego, CA, USA","institution_ids":["https://openalex.org/I36258959"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5009960666","display_name":"Michael Bouvet","orcid":"https://orcid.org/0000-0002-0086-2159","observed_orcids":["https://orcid.org/0000-0002-0086-2159"]},"institutions":[{"id":"https://openalex.org/I36258959","display_name":"University of California San Diego","ror":"https://ror.org/0168r3w48","country_code":"US","type":"education","lineage":["https://openalex.org/I36258959"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael Bouvet","raw_affiliation_strings":["University of California San Diego, Department of Surgery, San Diego, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of California San Diego, Department of Surgery, San Diego, CA, USA","institution_ids":["https://openalex.org/I36258959"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":true,"cited_by_count":28,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"16","issue":"7","first_page":"943","last_page":"947"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10231","display_name":"Pancreatic and Hepatic Oncology Research","score":0.836899995803833,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10231","display_name":"Pancreatic and Hepatic Oncology Research","score":0.836899995803833,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10063","display_name":"Nanoparticle-Based Drug Delivery","score":0.12449999898672104,"subfield":{"id":"https://openalex.org/subfields/2502","display_name":"Biomaterials"},"field":{"id":"https://openalex.org/fields/25","display_name":"Materials Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.030799999833106995,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/nab-paclitaxel","display_name":"nab-paclitaxel","score":0.9919999837875366},{"id":"https://openalex.org/keywords/pancreatic-cancer","display_name":"pancreatic cancer","score":0.9470000267028809},{"id":"https://openalex.org/keywords/gemcitabine-combination-therapy","display_name":"gemcitabine combination therapy","score":0.8270000219345093},{"id":"https://openalex.org/keywords/g2-m-phase","display_name":"G2/M phase","score":0.8360000252723694},{"id":"https://openalex.org/keywords/drug-delivery-systems","display_name":"drug delivery systems","score":0.640999972820282},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.6759999990463257},{"id":"https://openalex.org/keywords/treatment-resistance","display_name":"treatment resistance","score":0.5910000205039978},{"id":"https://openalex.org/keywords/cancer-nanomedicine","display_name":"cancer nanomedicine","score":0.718999981880188}],"concepts":[{"id":"https://openalex.org/C2777292972","wikidata":"https://www.wikidata.org/wiki/Q423762","display_name":"Paclitaxel","level":3,"score":0.8925908803939819},{"id":"https://openalex.org/C2780258809","wikidata":"https://www.wikidata.org/wiki/Q414143","display_name":"Gemcitabine","level":3,"score":0.8793807625770569},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7623560428619385},{"id":"https://openalex.org/C2780210213","wikidata":"https://www.wikidata.org/wiki/Q212961","display_name":"Pancreatic cancer","level":3,"score":0.7597532272338867},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.5190106630325317},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.508169412612915},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.45833733677864075},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.4529043138027191},{"id":"https://openalex.org/C2776125364","wikidata":"https://www.wikidata.org/wiki/Q169219","display_name":"Albumin","level":2,"score":0.4415782392024994},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.43036922812461853},{"id":"https://openalex.org/C29537977","wikidata":"https://www.wikidata.org/wiki/Q188941","display_name":"Cell cycle","level":3,"score":0.42849215865135193},{"id":"https://openalex.org/C2910430875","wikidata":"https://www.wikidata.org/wiki/Q7251413","display_name":"Nab-paclitaxel","level":4,"score":0.4152378439903259},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.3952363133430481},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.35325735807418823}],"mesh":[{"descriptor_ui":"D000093542","descriptor_name":"Gemcitabine","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000418","descriptor_name":"Albumins","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D003841","descriptor_name":"Deoxycytidine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D003841","descriptor_name":"Deoxycytidine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010190","descriptor_name":"Pancreatic Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D010190","descriptor_name":"Pancreatic Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D017239","descriptor_name":"Paclitaxel","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D053758","descriptor_name":"Nanoparticles","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1517/14656566.2015.1016912","doi":"https://doi.org/10.1517/14656566.2015.1016912","is_oa":true,"landing_page_url":"https://doi.org/10.1517/14656566.2015.1016912","pdf_url":"https://www.tandfonline.com/doi/pdf/10.1517/14656566.2015.1016912?needAccess=true&role=button","source":{"id":"https://openalex.org/S52020611","display_name":"Expert Opinion on Pharmacotherapy","issn_l":"1465-6566","issn":["1465-6566","1744-7666"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Pharmacotherapy","raw_type":"journal-article"},{"id":"pmid:25887245","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25887245","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert opinion on pharmacotherapy","raw_type":"Editorial"},{"id":"pmh:oai:pubmedcentral.nih.gov:5559227","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/5559227","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"Expert Opin Pharmacother","raw_type":"Text"},{"id":"pmh:oai:escholarship.org:ark:/13030/qt9h27w093","doi":null,"is_oa":false,"landing_page_url":"https://escholarship.org/uc/item/9h27w093","pdf_url":null,"source":{"id":"https://openalex.org/S4306400115","display_name":"eScholarship (California Digital Library)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I2801248553","host_organization_name":"California Digital Library","host_organization_lineage":["https://openalex.org/I2801248553"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Expert Opinion on Pharmacotherapy, vol 16, iss 7","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1517/14656566.2015.1016912","doi":"https://doi.org/10.1517/14656566.2015.1016912","is_oa":true,"landing_page_url":"https://doi.org/10.1517/14656566.2015.1016912","pdf_url":"https://www.tandfonline.com/doi/pdf/10.1517/14656566.2015.1016912?needAccess=true&role=button","source":{"id":"https://openalex.org/S52020611","display_name":"Expert Opinion on Pharmacotherapy","issn_l":"1465-6566","issn":["1465-6566","1744-7666"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Pharmacotherapy","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.98580002784729,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G3167364872","display_name":"Color-Coded Imaging of Pancreatic Cancer Microenvironment for Drug Discovery","funder_award_id":"5r01ca132971-05","funder_id":"https://openalex.org/F4320332161","funder_display_name":"National Institutes of Health"},{"id":"https://openalex.org/G483852586","display_name":null,"funder_award_id":"R01-CA132971","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G571379083","display_name":null,"funder_award_id":"CA132791","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320332161","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88"},{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2004302235.pdf","grobid_xml":"https://content.openalex.org/works/W2004302235.grobid-xml"},"referenced_works_count":18,"referenced_works":["https://openalex.org/W1524092019","https://openalex.org/W1844255926","https://openalex.org/W1969353138","https://openalex.org/W1998149120","https://openalex.org/W2004573663","https://openalex.org/W2012110463","https://openalex.org/W2012873903","https://openalex.org/W2055091294","https://openalex.org/W2072826056","https://openalex.org/W2080829828","https://openalex.org/W2100808704","https://openalex.org/W2118878272","https://openalex.org/W2134495718","https://openalex.org/W2159118239","https://openalex.org/W2165480504","https://openalex.org/W2170202192","https://openalex.org/W2222298264","https://openalex.org/W2338751106"],"related_works":["https://openalex.org/W2586286736","https://openalex.org/W2036622560","https://openalex.org/W2061501822","https://openalex.org/W4251787467","https://openalex.org/W2072225209","https://openalex.org/W2055840440","https://openalex.org/W7100839602","https://openalex.org/W2168580276","https://openalex.org/W6966911512","https://openalex.org/W1969353138"],"abstract_inverted_index":{"Nanoparticle":[0],"albumin-bound":[1],"(nab)-paclitaxel":[2],"is":[3,14],"paclitaxel":[4],"linked":[5],"to":[6,62,116,120,145],"albumin":[7],"nanoparticles,":[8],"which":[9,79],"makes":[10],"it":[11],"soluble":[12],"and":[13,39,122],"an":[15,18],"example":[16],"of":[17,20,27,41,86,99,130],"application":[19],"nanotechnology":[21,28],"for":[22,33],"cancer":[23,118],"treatment.":[24],"The":[25],"development":[26],"as":[29,65,77,143,155],"a":[30,102,127,151],"delivery":[31],"system":[32],"nab-paclitaxel":[34,144],"has":[35,54],"improved":[36,56],"the":[37,83,87,96,131,136],"pharmacokinetics":[38],"pharmacodynamics":[40],"paclitaxel,":[42],"in":[43,50,58,67,82,101,106,111,126,135,150],"part":[44],"by":[45],"decreasing":[46],"its":[47],"hydrophobicity.":[48],"Nab-paclitaxel":[49],"combination":[51],"with":[52],"gemcitabine":[53,63],"slightly":[55],"survival":[57],"pancreatic":[59,156],"cancer,":[60],"compared":[61],"alone,":[64],"demonstrated":[66],"Phase":[68],"III":[69],"clinical":[70],"trials.":[71],"Cell":[72],"cycle":[73,121],"phase-specific":[74],"drugs,":[75],"such":[76,142,154],"nab-paclitaxel,":[78],"target":[80],"cells":[81,100,119],"G2/M":[84],"phase":[85,129],"cell":[88,132],"cycle,":[89,133],"can":[90],"only":[91],"have":[92,146],"limited":[93],"efficacy":[94],"since":[95],"vast":[97],"majority":[98],"tumor":[103,153],"are":[104],"quiescent":[105],"G0/G1":[107],"phase.":[108],"Recent":[109],"advances":[110],"our":[112],"laboratory":[113],"on":[114],"how":[115],"decoy":[117],"then":[123],"trap":[124],"them":[125],"sensitive":[128],"can,":[134],"hopefully":[137],"near":[138],"future,":[139],"allow":[140],"drugs":[141],"high":[147],"efficacy,":[148],"even":[149],"treatment-resistant":[152],"cancer.":[157]},"counts_by_year":[{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":4},{"year":2018,"cited_by_count":4},{"year":2017,"cited_by_count":4},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}